Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 9:45 am EDT on Friday, September 5, 2008, at the Thomas Weisel Partners Healthcare Conference in Boston.

The update will include information about Geron’s portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1). The presentation will also include a review of the company’s human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).

The audio and slide presentation will be available at the following Web site address: http://www.veracast.com/webcasts/twp/healthcare08/44304405.cfm. The presentation will be archived for replay at the same address within 24 hours of the presentation for a period of 30 days until October 4, 2008.

Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are based on our core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.

Contacts:

Geron Corporation
Anna Krassowska, 650-473-7765
(Investor and Media Relations)
info@geron.com